Medite Cancer Diagnostics, Inc. - FORM 10-K - EX-32.1 - CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER OF THE COMPANY PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002. - April 12, 2016

Attached files

file filename
EX-32.2 - CERTIFICATION OF THE CHIEF FINANCIAL OFFICER OF THE COMPANY PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002. - Medite Cancer Diagnostics, Inc.ex32-2.htm
10-K - FORM 10-K - Medite Cancer Diagnostics, Inc.medite105_dec312015.htm
EX-31.2 - CERTIFICATION OF THE CHIEF FINANCIAL OFFICER OF THE COMPANY PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002. - Medite Cancer Diagnostics, Inc.ex31-2.htm
EX-31.1 - CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER OF THE COMPANY PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002. - Medite Cancer Diagnostics, Inc.ex31-1.htm
 
Exhibit 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Annual Report (the “report”) of MEDITE Cancer Diagnostics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2015, I, Michaela Ott., the Chief Executive Officer of the Company, do hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to the best of my knowledge:
 
(1)      the report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2)      the information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:  April 12, 2016
/s/ Michaela Ott
 
Michaela Ott
 
Chief Executive Officer
 
 
 

Medite Cancer Diagnostics, Inc. Reports